- Home
- PHAT vs ASA Comparison
PHAT vs ASA Comparison
Compare PHAT & ASA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ASA
- Stock Information
- Founded
- PHAT 2018
- ASA 1958
- Country
- PHAT United States
- ASA United States
- Employees
- PHAT N/A
- ASA N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ASA Precious Metals
- Sector
- PHAT Health Care
- ASA Industrials
- Exchange
- PHAT Nasdaq
- ASA Nasdaq
- Market Cap
- PHAT 640.9M
- ASA 622.9M
- IPO Year
- PHAT 2019
- ASA N/A
- Fundamental
- Price
- PHAT $8.35
- ASA $31.11
- Analyst Decision
- PHAT Strong Buy
- ASA
- Analyst Count
- PHAT 5
- ASA 0
- Target Price
- PHAT $16.40
- ASA N/A
- AVG Volume (30 Days)
- PHAT 937.1K
- ASA 83.2K
- Earning Date
- PHAT 08-07-2025
- ASA 08-12-2025
- Dividend Yield
- PHAT N/A
- ASA 0.19%
- EPS Growth
- PHAT N/A
- ASA N/A
- EPS
- PHAT N/A
- ASA 14.01
- Revenue
- PHAT $81,859,000.00
- ASA $3,923,667.00
- Revenue This Year
- PHAT $195.03
- ASA N/A
- Revenue Next Year
- PHAT $106.77
- ASA N/A
- P/E Ratio
- PHAT N/A
- ASA $2.21
- Revenue Growth
- PHAT 3055.70
- ASA 45.39
- 52 Week Low
- PHAT $2.21
- ASA $17.42
- 52 Week High
- PHAT $19.71
- ASA $35.00
- Technical
- Relative Strength Index (RSI)
- PHAT 47.45
- ASA 40.46
- Support Level
- PHAT $7.61
- ASA $30.95
- Resistance Level
- PHAT $9.23
- ASA $32.56
- Average True Range (ATR)
- PHAT 0.66
- ASA 0.87
- MACD
- PHAT -0.08
- ASA -0.25
- Stochastic Oscillator
- PHAT 30.64
- ASA 4.52
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.